Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Globe Newswire•02/10/2026•08:05 ET
0
Key Highlights
- ➤CNTY-813 maintained glycemic control in diabetic mice for over eleven months
- ➤Five clinical-scale batches produced consistent CNTY-813 final product profiles
- ➤CNTY-813 IND submission remains on track for Q4 2026
- ➤Initial CNTY-813 clinical data anticipated in the second half of 2027
Expert Statements
Brent Pfeiffenberger, Chief Executive Officer of Century Therapeutics
“The data presented at EASD build on the nonclinical package we presented at ADA in June and highlight our continued execution on bringing CNTY-813 into the clinic”
Brent Pfeiffenberger, Chief Executive Officer of Century Therapeutics
“Following our pre-IND meeting, in which we reached general alignment with FDA on our nonclinical package, Phase 1 manufacturing process and proposed Phase 1/2 trial design, we remain on track to submit the CNTY-813 IND in the fourth quarter of this year with initial clinical data anticipated in the second half of 2027.”
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes
CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027
Get started
Create a free account to read the full story.